| Bioactivity | Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (KATP) channels among β cells of pancreatic islets of Langerhans[1][2]. | ||||||||||||
| Target | IC50: 6.4 nM ATP-sensitive potassium (KATP) channels in primary mouse pancreatic β cells | ||||||||||||
| Invitro | Glipizide inhibits ATP-sensitive potassium (KATP) channels in primary mouse pancreatic β cells (IC50= 6.4 nM)[1]. | ||||||||||||
| Name | Glipizide | ||||||||||||
| CAS | 29094-61-9 | ||||||||||||
| Formula | C21H27N5O4S | ||||||||||||
| Molar Mass | 445.54 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. B J Zünkler, et al. Concentration-dependent effects of tolbutamide, meglitinide, glipizide, glibenclamide and diazoxide on ATP-regulated K+ currents in pancreatic B-cells. Naunyn Schmiedebergs Arch Pharmacol. 1988 Feb;337(2):225-30. [2]. Glipizide. From Wikipedia |